Hormonal
High body mass index (BMI) is a strong independent risk factor for the development and progression of chronic kidney disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.
Maintaining a healthy weight is one of the most effective ways to protect your kidneys. Excess body weight forces your kidneys to work harder (hyperfiltration), which can cause long-term damage. Focus on sustainable lifestyle changes like balanced nutrition and regular physical activity to manage weight, especially if you have a family history of kidney issues or high blood pressure.
A high body mass index (BMI) is one of the strongest risk factors for new-onset chronic kidney disease. In individuals affected by obesity, a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased bodyweight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing chronic kidney disease in the long term.
Why this rating
Based on numerous large population-based studies and meta-analyses cited in the review, though it is a review paper rather than a single RCT.
Source
Obesity and kidney disease: hidden consequences of the epidemic
Csaba P. Kövesdy et al. · Journal of Endocrinology Metabolism and Diabetes of South Africa · 2017
DOI 10.1080/16089677.2017.1299975
More from this paper
- Obesity increases the risk of kidney stones (nephrolithiasis) and kidney cancer through mechanisms involving insulin resistance, acidic urine, and adipose-derived inflammatory factors.Good
- Weight loss interventions, including lifestyle changes and ACE inhibition, can reduce blood pressure, glomerular hyperfiltration, and proteinuria in obese patients with CKD.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →